Sections
| Title | Starting Page | Number of Pages |
|---|
| Table of Contents | 2 | 40 |
| List of Tables | 36 | 5 |
| List of Figures | 41 | 1 |
| Introduction | 42 | 1 |
| Global Markets Direct Report Coverage | 42 | 1 |
| Liver Cancer Overview | 43 | 1 |
| Therapeutics Development | 44 | 2 |
| Pipeline Products for Liver Cancer Overview | 44 | 1 |
| Pipeline Products for Liver Cancer Comparative Analysis | 45 | 1 |
| Liver Cancer Therapeutics under Development by Companies | 46 | 13 |
| Liver Cancer Therapeutics under Investigation by Universities/Institutes | 59 | 2 |
| Liver Cancer Pipeline Products Glance | 61 | 3 |
| Late Stage Products | 61 | 1 |
| Clinical Stage Products | 62 | 1 |
| Early Stage Products | 63 | 1 |
| Liver Cancer Products under Development by Companies | 64 | 19 |
| Liver Cancer Products under Investigation by Universities/Institutes | 83 | 3 |
| Liver Cancer Companies Involved in Therapeutics Development | 86 | 170 |
| 4SC AG | 86 | 1 |
| AB Science SA | 87 | 1 |
| Acceleron Pharma, Inc. | 88 | 1 |
| ACROVIS Pharma AG | 89 | 1 |
| Adaptimmune Therapeutics Plc | 90 | 1 |
| Aduro BioTech, Inc. | 91 | 1 |
| Advanced Accelerator Applications S.A. | 92 | 1 |
| Advenchen Laboratories, LLC | 93 | 1 |
| Alfact Innovation | 94 | 1 |
| Alnylam Pharmaceuticals, Inc. | 95 | 1 |
| American Gene Technologies International Inc. | 96 | 1 |
| Amgen Inc. | 97 | 1 |
| AndroScience Corporation | 98 | 1 |
| APAvadis Biotechnologies Srl | 99 | 1 |
| Arbutus Biopharma Corporation | 100 | 1 |
| ArQule, Inc. | 101 | 1 |
| Array BioPharma Inc. | 102 | 1 |
| Arrowhead Pharmaceuticals, Inc. | 103 | 1 |
| Astex Pharmaceuticals, Inc. | 104 | 1 |
| AstraZeneca Plc | 105 | 1 |
| AVEO Pharmaceuticals, Inc. | 106 | 1 |
| Bayer AG | 107 | 1 |
| Beijing Kawin Technology Share-Holding Co., Ltd. | 108 | 1 |
| Betta Pharmaceuticals Co. Ltd. | 109 | 1 |
| Bio-Cancer Treatment International Limited | 110 | 1 |
| BioCancell Ltd | 111 | 1 |
| Biogazelle | 112 | 1 |
| Biomics Biotechnologies Co., Ltd. | 113 | 1 |
| Bioneer Corporation | 114 | 1 |
| BioStar Pharmaceuticals, Inc. | 115 | 1 |
| Blueprint Medicines Corporation | 116 | 1 |
| Boehringer Ingelheim GmbH | 117 | 1 |
| Boston Biomedical, Inc. | 118 | 1 |
| Can-Fite BioPharma Ltd. | 119 | 1 |
| CASI Pharmaceuticals Inc. | 120 | 1 |
| CCRP Therapeutics GmbH | 121 | 1 |
| Celgene Corporation | 122 | 1 |
| Celldex Therapeutics, Inc. | 123 | 1 |
| Celprogen, Inc. | 124 | 1 |
| Celsion Corporation | 125 | 1 |
| China Medical System Holdings Limited | 126 | 1 |
| Chiome Bioscience, Inc. | 127 | 1 |
| Chipscreen Biosciences Ltd | 128 | 1 |
| Chroma Therapeutics Limited | 129 | 1 |
| CohBar, Inc. | 130 | 1 |
| CytRx Corporation | 131 | 1 |
| CZ BioMed Corp | 132 | 1 |
| Daiichi Sankyo Company, Limited | 133 | 1 |
| Delcath Systems, Inc. | 134 | 1 |
| Dicerna Pharmaceuticals, Inc. | 135 | 1 |
| Digna Biotech, S.L. | 136 | 1 |
| Double Bond Pharmaceutical International AB | 137 | 1 |
| Eisai Co., Ltd. | 138 | 1 |
| Eli Lilly and Company | 139 | 1 |
| Endocyte, Inc. | 140 | 1 |
| eTheRNA Immunotherapies NV | 141 | 1 |
| Eureka Therapeutics, Inc. | 142 | 1 |
| Exelixis, Inc. | 143 | 1 |
| F. Hoffmann-La Roche Ltd. | 144 | 1 |
| Genelux Corporation | 145 | 1 |
| Genoscience Pharma | 146 | 1 |
| Genosco | 147 | 1 |
| GenSpera, Inc. | 148 | 1 |
| GlaxoSmithKline Plc | 149 | 1 |
| Golden Biotechnology Corp. | 150 | 1 |
| Green Cross Cell Corporation | 151 | 1 |
| H3 Biomedicine Inc. | 152 | 1 |
| HanAll Biopharma Co., Ltd. | 153 | 1 |
| HEC Pharm Co., Ltd. | 154 | 1 |
| HitGen LTD | 155 | 1 |
| Horizon Pharma Plc | 156 | 1 |
| Huperion Sarl | 157 | 1 |
| Immunicum AB | 158 | 1 |
| Immunitor, Inc. | 159 | 1 |
| Immunomedics, Inc. | 160 | 1 |
| Immunovative Therapies, Ltd. | 161 | 1 |
| IMPACT Therapeutics, Inc. | 162 | 1 |
| In-Cell-Art S.A.S. | 163 | 1 |
| Incanthera Ltd. | 164 | 1 |
| Incuron, LLC | 165 | 1 |
| InteRNA Technologies B.V. | 166 | 1 |
| Jasco Pharmaceuticals, LLC. | 167 | 1 |
| Jenrin Discovery, Inc. | 168 | 1 |
| Johnson &Johnson | 169 | 1 |
| JW Pharmaceutical Corporation | 170 | 1 |
| KAHR medical Ltd. | 171 | 1 |
| Karcinolys SAS | 172 | 1 |
| Keystone Nano, Inc. | 173 | 1 |
| Kite Pharma, Inc. | 174 | 1 |
| Komipharm International Co., Ltd. | 175 | 1 |
| Kowa Company, Ltd. | 176 | 1 |
| Les Laboratoires Servier SAS | 177 | 1 |
| Ligand Pharmaceuticals, Inc. | 178 | 1 |
| Lixte Biotechnology Holdings, Inc. | 179 | 1 |
| Lytix Biopharma AS | 180 | 1 |
| MaxCyte, Inc. | 181 | 1 |
| MedImmune, LLC | 182 | 1 |
| Medivation, Inc. | 183 | 1 |
| Medivir AB | 184 | 1 |
| Merck &Co., Inc. | 185 | 1 |
| Merck KGaA | 186 | 1 |
| Merrimack Pharmaceuticals, Inc. | 187 | 1 |
| Midatech Pharma Plc | 188 | 1 |
| Millennium Pharmaceuticals, Inc. | 189 | 1 |
| Mirna Therapeutics, Inc. | 190 | 1 |
| Molecular Partners AG | 191 | 1 |
| MolMed S.p.A. | 192 | 1 |
| MultiCell Technologies, Inc. | 193 | 1 |
| Nimbus Therapeutics, LLC | 194 | 1 |
| NormOxys, Inc. | 195 | 1 |
| Northwest Biotherapeutics, Inc. | 196 | 1 |
| Novartis AG | 197 | 1 |
| NovaTarg Therapeutics, Inc | 198 | 1 |
| Nymox Pharmaceutical Corporation | 199 | 1 |
| Omeros Corporation | 200 | 1 |
| Omnitura Therapeutics Inc. | 201 | 1 |
| Oncolys BioPharma Inc. | 202 | 1 |
| OncoMed Pharmaceuticals, Inc. | 203 | 1 |
| OncoTherapy Science, Inc. | 204 | 1 |
| Oneness Biotech Co., Ltd. | 205 | 1 |
| Ono Pharmaceutical Co., Ltd. | 206 | 1 |
| Onxeo SA | 207 | 1 |
| OPKO Health, Inc. | 208 | 1 |
| Oribase Pharma | 209 | 1 |
| Otsuka Holdings Co., Ltd. | 210 | 1 |
| Panacea Pharmaceuticals, Inc. | 211 | 1 |
| Peptinov SAS | 212 | 1 |
| Pfizer Inc. | 213 | 1 |
| Pharma Mar, S.A. | 214 | 1 |
| PharmAbcine, Inc. | 215 | 1 |
| PharmaEssentia Corporation | 216 | 1 |
| Phosplatin Therapeutics LLC | 217 | 1 |
| Polaris Pharmaceuticals, Inc. | 218 | 1 |
| Progen Pharmaceuticals Limited | 219 | 1 |
| ProMetic Life Sciences Inc. | 220 | 1 |
| Provecs Medical GmbH | 221 | 1 |
| Provectus Biopharmaceuticals, Inc. | 222 | 1 |
| Quimatryx, S.L. | 223 | 1 |
| Raptor Pharmaceutical Corp. | 224 | 1 |
| RedHill Biopharma Ltd. | 225 | 1 |
| Regen BioPharma, Inc. | 226 | 1 |
| Regulus Therapeutics Inc. | 227 | 1 |
| Rigontec GmbH | 228 | 1 |
| Saronic Biotechnology, Inc. | 229 | 1 |
| Savoy Pharmaceuticals, Inc. | 230 | 1 |
| Shenogen Pharma Group Ltd. | 231 | 1 |
| Shenzen SiBiono GeneTech Co., Ltd. | 232 | 1 |
| Silence Therapeutics Plc | 233 | 1 |
| Sillajen Biotherapeutics | 234 | 1 |
| Simcere Pharmaceutical Group | 235 | 1 |
| Synovo GmbH | 236 | 1 |
| Taiwan Liposome Company, Ltd. | 237 | 1 |
| Tara Immuno-Oncology Therapeutics LLC | 238 | 1 |
| Targetome | 239 | 1 |
| Therapure Biopharma Inc. | 240 | 1 |
| Theravectys SA | 241 | 1 |
| Tiziana Life Sciences Plc | 242 | 1 |
| Toko Pharmaceutical Industries Co., Ltd. | 243 | 1 |
| TRACON Pharmaceuticals, Inc. | 244 | 1 |
| Transgene Biotek Limited | 245 | 1 |
| Tumorend, LLC | 246 | 1 |
| UbiVac, LLC | 247 | 1 |
| VasGene Therapeutics, Inc. | 248 | 1 |
| Vaxon Biotech | 249 | 1 |
| Vect-Horus S.A.S. | 250 | 1 |
| Verlyx Pharma Inc. | 251 | 1 |
| VG Life Sciences, Inc. | 252 | 1 |
| Vicus Therapeutics, LLC | 253 | 1 |
| Virttu Biologics Limited | 254 | 1 |
| Vyriad | 255 | 1 |
| Liver Cancer Therapeutics Assessment | 256 | 27 |
| Assessment by Monotherapy Products | 256 | 1 |
| Assessment by Combination Products | 257 | 1 |
| Assessment by Target | 258 | 10 |
| Assessment by Mechanism of Action | 268 | 11 |
| Assessment by Route of Administration | 279 | 2 |
| Assessment by Molecule Type | 281 | 2 |
| Drug Profiles | 283 | 749 |
| (etodolac + propranolol hydrochloride) Drug Profile | 283 | 2 |
| ABC-294640 Drug Profile | 285 | 5 |
| AC-2010 Drug Profile | 290 | 1 |
| AC-915 Drug Profile | 291 | 1 |
| ACR-488 Drug Profile | 292 | 1 |
| AdVince Drug Profile | 293 | 1 |
| AG-1103 Drug Profile | 294 | 1 |
| AL-3818 Drug Profile | 295 | 2 |
| AL-8326 Drug Profile | 297 | 1 |
| ALF-2111 Drug Profile | 298 | 1 |
| AlloVax Drug Profile | 299 | 2 |
| ALN-VSP Drug Profile | 301 | 4 |
| AMB-8LK Drug Profile | 305 | 1 |
| amcasertib Drug Profile | 306 | 2 |
| AMG-337 Drug Profile | 308 | 2 |
| Antibodies to Inhibit FRMD4A for Oncology Drug Profile | 310 | 1 |
| Antibody to Antagonize Fzd2 Receptor for Hepatocellular Carcinoma Drug Profile | 311 | 1 |
| Antisense Oligonucleotide to Inhibit HNF4A for HCV Infection Associated Hepatocellular Carcinoma Drug Profile | 312 | 1 |
| Antisense RNAi Oligonucleotide for Hepatocellular Carcinoma Drug Profile | 313 | 1 |
| Antisense RNAi Oligonucleotide for Hepatocellular Carcinoma Drug Profile | 314 | 1 |
| Antisense RNAi Oligonucleotide for Liver Cancer Drug Profile | 315 | 1 |
| Antisense RNAi Oligonucleotide for Liver Diseases Drug Profile | 316 | 1 |
| Antisense RNAi Oligonucleotide to Inhibit Beta Catenin for Oncology Drug Profile | 317 | 1 |
| antroquinonol Drug Profile | 318 | 1 |
| apatinib Drug Profile | 319 | 3 |
| APTA-16 Drug Profile | 322 | 1 |
| APV-224 Drug Profile | 323 | 1 |
| ARQ-092 Drug Profile | 324 | 3 |
| ASC-JM.Z1 Drug Profile | 327 | 1 |
| atezolizumab Drug Profile | 328 | 11 |
| AV-203 Drug Profile | 339 | 3 |
| AZ-709 Drug Profile | 342 | 1 |
| AZD-9150 Drug Profile | 343 | 3 |
| BC-821 Drug Profile | 346 | 1 |
| BCT-100 Drug Profile | 347 | 2 |
| binimetinib Drug Profile | 349 | 7 |
| BLU-554 Drug Profile | 356 | 2 |
| BLU-9931 Drug Profile | 358 | 1 |
| BPI-9016 Drug Profile | 359 | 1 |
| brivanib alaninate Drug Profile | 360 | 3 |
| bromopyruvate Drug Profile | 363 | 1 |
| buparlisib hydrochloride Drug Profile | 364 | 5 |
| cabozantinib s-malate Drug Profile | 369 | 17 |
| capmatinib Drug Profile | 386 | 3 |
| CC-122 Drug Profile | 389 | 2 |
| CCV-3611643 Drug Profile | 391 | 1 |
| CDX-1401 Drug Profile | 392 | 3 |
| Cellular Immunotherapy for Hepatocellular Carcinoma Drug Profile | 395 | 1 |
| Cellular Immunotherapy for Hepatocellular Carcinoma Drug Profile | 396 | 1 |
| Cellular Immunotherapy for Hepatocellular Carcinoma Drug Profile | 397 | 1 |
| Cellular Immunotherapy for Hepatocellular Carcinoma Drug Profile | 398 | 1 |
| Cellular Immunotherapy for Metastatic Hepatocellular Carcinoma Drug Profile | 399 | 1 |
| Cellular Immunotherapy for Oncology Drug Profile | 400 | 1 |
| Cellular Immunotherapy for Oncology Drug Profile | 401 | 1 |